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ABSTRACT  
Bacterial vaginosis (BV) is the main cause of abnormal vaginal discharge in women of reproductive 
age. Gardnerella vaginalis, has been detected in almost all women with BV. However, there is limited 
information on the genetic diversity of G. vaginalis isolated from BV intermediate and positive cases. 
In this study we investigated the genetic diversity of G. vaginalis strains from South African pregnant 
women.  
Vaginal swabs were characterized by the Nugent method. A total of n= 87 samples were included in the 
genetic analysis, (n=50 BV positive) and (n=37 BV intermediate). The presence of G. vaginalis was 
detected by PCR using bacterium specific 16S rRNA primers. All PCR positive amplicons were 
sequenced by the Sanger method and the edited sequence data was used for the phylogenetic analysis 
using the PHYLIP software. The sialidase A gene was amplified by PCR using specific primers and the 
copy numbers of sialidase A gene was quantified by droplet digital PCR. To assess the diversity of the 
sialidase A gene, Sanger sequencing was performed.  
The 16S rRNA gene from G. vaginalis was amplified in all BV positive and BV intermediate samples. 
All PCR amplicons were successfully sequenced and the nucleotide BLAST results revealed 100% 
identify to G. vaginalis.  The phylogenetic analysis revealed that there is no diversity in G. vaginalis 
present in BV positive and intermediate cases. The phylogenetic tree of sialidase A sequences from 
intermediate and positive BV cases revealed two major clades which showed differences related to 
sialidase A copy number. Quantification of sialidase A showed that the average number of copies per 
cell was much higher in the BV positive group compared to the intermediate group. Some of the 
intermediate cases showed high copy numbers for the virulence gene and clustered with the BV positive 
cases.  
In the present study the 16S rRNA sequences of the G. vaginalis from BV intermediate and positive 
women showed that there is no genetic diversity in G. vaginalis detected in BV positive and intermediate 
samples. The phylogenetic tree of sialidase A gene sequences of intermediate and positive BV revealed 
two major clades which showed differences related to sialidase A copy number. This data was 
previously lacking in our setting, especially in a pregnant population. We further demonstrate for the 
first time that the genetic information present within the sialidase A gene has a direct influence on BV 
status.
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CHAPTER 1  
INTRODUCTION 
  
Bacterial vaginosis (BV) is a polymicrobial syndrome that affects women of reproductive age and is the 
most prevalent cause of symptomatic vaginal discharge  (1). Bacterial vaginosis has been associated 
with complications of reproductive health, such as preterm birth and acquisition or transmission of 
sexually transmitted infections (STIs), including human immunodeficiency virus (HIV) infect ion. 
Facultative anaerobic microorganisms such as  Gardnerella vaginalis, Atopobium vaginae, Mobiluncus 
mulieris, Prevotella bivia, Peptostreptococcus and Bacteroides have been associated with BV (2).  
The cause of BV is not fully understood. However, it has been suggested that it is transmissible, and 
that G. vaginalis may be the main causative agent (3). Studies using enzymatic assays to define G. 
vaginalis biotypes, as well as more recent genomic comparisons of G. vaginalis isolates from 
symptomatic and asymptomatic women, suggested that some strains of G. vaginalis may play a key role 
in the pathogenesis of BV (4-6) G. vaginalis has appeared to be the most virulent BV associated 
anaerobe (7), demonstrating greater adherence to vaginal cells, cytotoxicity and biofilm producing 
capacity (8). These virulence factors suggest that G. vaginalis plays a key role in BV biofilms 
development.  
Conventional microbial techniques are useful screening tools for the identification of women with BV. 
However, they do not allow the prediction of the clinical burden associated with BV (9) . The analysis 
of complex bacterial communities is hindered by conventional culture-dependent methods and by 
biochemical identification methods, as they leave many microorganisms uncultured and unidentified 
(9). The present molecular methods make it possible to differentiate between the closely related species 
of bacteria (10). Detailed information of complex microbial community can also be acquired from the 
phylogenetic analysis of 16S rDNA sequences obtained directly from samples by PCR amplification, 
cloning and sequencing so that unculturable species are also included (11). 
Very little is known about the genetics of G. vaginalis, its physiology and the diversity of strains isolated 
from BV intermediate and BV positive women. Recent data has shown that the pathogenic strength or 
potential of G. vaginalis may be underestimated (12). To date, there have been no studies in our setting 
that have investigated the diversity of G. vaginalis detected in pregnant women. In this study, we aimed 
to investigate the diversity of the 16S ribosomal RNA (rRNA) of G. vaginalis detected in pregnant 
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women diagnosed as BV positive and intermediate. The findings of this study will add to the body of 
knowledge regarding the diversity of G. vaginalis across different BV states.   
                                        
  
CHAPTER 2  
2.1 LITERATURE REVIEW 
  
2.1.1 Overview  
Bacterial vaginosis (BV) is the most common condition that affects women of child-bearing age (1). It 
is a condition whereby predominant Lactobacillus spp. in the healthy vagina, are replaced by a mixed 
flora including Prevotella bivia, Prevotella disiens, Porphyromonas spp. Mobiluncus spp. and 
Peptostreptococcus spp (2). Recent studies have shown an increased risk associated with multiple sexual 
partners (13). This condition BV, has been associated with adverse pregnancy outcomes, including 
premature rupture of membranes, chorioamnionitis, postpartum endometritis; and urinary tract 
infections (12-14). The mechanisms by which the BV-associated flora causes the signs of BV are not 
well understood, but the role for H2O2 producing Lactobacillus spp. in protecting against colonization 
by catalase-negative anaerobic bacteria has been reported (3).  
  
  
2.1.2 History  
  
Gardnerella vaginalis was originally discovered by Leopold (15)  who described this microorganism as 
a “Haemophilus-like” species associated with prostatis and cervicitis (16). Gardner and Dukes (17) were 
the first to describe the microorganism in relation to bacterial vaginosis (BV). Due to its morphology, 
its apparent negative reaction to Gram staining and inability to grow on agar media lacking blood, 
researchers were convinced that they were dealing with a new Haemophilus species. They therefore 
named it based on its origin Haemophilus vaginalis (18)After extensive research it eventually became 
apparent that, unlike other members of the Haemophilus genus, ‘H. vaginalis’ infrequently had a 
positive reaction to gram staining and did not require either hemin nor NAD for its growth. The 
microorganism was then temporarily placed into the Corynebacterium genus, and was referred to as 
Corynebacterium vaginale for quite some time (18, 19). However, since the bacterium was catalase 
negative and it lacked arabinose in its cell wall (17), it therefore did not fit into the description of the 
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Corynebacterium genus. Finally, two large taxonomic studies evaluating multiple criteria revealed the 
lack of similarities between “H. vaginalis” and other established genera (17, 20), a new genus named 
Gardnerella was proposed, with G. vaginalis being the only species in it.  
  
2.1.3 Morphology  
  
The cells of G. vaginalis are small, pleomorphic rods with average dimensions of 0.4 by 1.0–1.5 µm 
(15, 17), however, the length of some cells may reach up to 2–3 µm (20, 21). The cell size and 
morphology largely depend on their growth conditions and on their physiological state (17, 22). This 
bacterium is immotile, with the cells frequently occurring in clumps in vaginal smears and when grown 
in liquid media (20, 21). G. vaginalis, has a gram-positive cell wall (23), however due to its thin cell 
wall its gram staining varies from negative to positive it is therefore described as a Gram variable 
microorganism (16).  G. vaginalis has fimbriae (pili) which are 3 to 7.5 nm in diameter covering the 
cell surface (24). The outer fibrillar coat is responsible for the attachment of G. vaginalis to the 
exfoliated vaginal epithelial cells also known as clue cells (24). Both fimbriae and exopolysaccharides 
are thought to be involved in attachment of G. vaginalis to the vaginal epithelium in vivo (16, 24). The 
cells of G. vaginalis are non-sporulating, they lack flagella, and they do not possess a typical capsule 
(20). G. vaginalis possess pili with a diameter 3 to 7.5nm. The presence of pili is more frequent in 
clinically isolated compared to laboratory cultured strains (25).  
  
  
  
Figure 1: A: G. vaginalis attached to exfoliated vaginal epithelial cells (clue cells). B: G.  
vaginalis as seen under microscopy after gram staining . (Centres for Disease Control 
and Prevention, 2010) 
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2.1.4 Growth requirements, nutrition and metabolism  
  
Gardnerella vaginalis is a facultative anaerobe and uses carbohydrates as its major energy source (20). 
This microorganism has a fermentative metabolism and acetic acid is a major product (26). G. vaginalis 
grows well in microaerophilic conditions in 5-7% CO2. Optimum growth of G. vaginalis occurs at 
temperatures between 35 and 370C, however, growth can occur between 25- 450C . Optimum growth 
occurs at a pH between 6 and 6.5, no growth occurs at pH 4 and slight growth occurs at pH 4.5 and 8 
(20). This micro-organism is fastidious, but it does not require either hemin or Nicotinamide Adenine 
Dinucleotide (NAD) for growth. As revealed by biochemical tests G. vaginalis is catalase-, oxidase- 
and β-glucosidase negative. It can ferment starch, dextrin, sucrose, glucose, fructose, ribose, maltose 
and raffinose. In addition, some strains of G. vaginalis can also ferment xylose and trehalose. However, 
G. vaginalis is unable to ferment rhamnose, melibiose, mannitol, and sorbitol (6). Furthermore, G. 
vaginalis can hydrolyze hippurate but not gelatin or esculin. This microorganism is also positive for α-
glucosidase activity and for β-hemolysis on human blood, but not sheep’s blood. Iron plays an important 
role in the growth of most pathogens (27). Jarosik et al 1998, studied the ability of G. vaginalis strains 
to acquire iron from the medium. Interestingly, all the strains they studied were able to acquire iron 
from ferric and ferrous inorganic substrates as well as hemin, catalase, haemoglobin, lactoferrin but not 
transferrin (27). Studies that analysed the genome of G. vaginalis revealed that the microorganism lacks 
enzymes in biochemical pathways that are involved in amino acid synthesis. It was predicted that G. 
vaginalis can synthesize some but not all purines and pyrimidine bases (6).   
  
2.2 Transmission and Pathogenesis  
  
Gardnerella vaginalis as a causative agent of  BV adheres to host cell, multiplies and produce biofilms 
(28). In 2014 Schwebeke et al reported that G. vaginalis is transmitted through sexually activity with 
an infected partner (29). G. vaginalis has necessary virulence factors to adhere to host vaginal 
epithelium to compete with normal vaginal flora for dominance. In another study, they suggested that it 
is possible that G. vaginalis, lowers the reduction-oxidation potential in the vaginal microbiome through 
its metabolic pathways and ability to form biofilm (30). Biofilm is essential for the survival of BV 
associated pathogens in the vagina, enhancing a scaffold environment for the growth of anaerobes such 
as Atopobium vaginae and Prevotella spp. (31). Biofilm formation has been reported to be the key for 
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the development of this condition as it provides elevated antibiotic tolerance and resistance to host 
immune defenses thereby resulting in the recurrent nature of this syndrome (7). Sialidase which is 
produced by other strains of G. vaginalis, may enhance production of biofilm through its mucinase 
activity (32). The neurominidase sialidase produced by some strains of G. vaginalis interferes with host 
immune modulation resulting in  adverse pregnancy outcomes (32). Sialidase activity in G. vaginalis 
was first described in 1984 (33). Sialidase also known as neuraminidases is a known virulence factor as 
it can invade and destroy tissue (34).   
Vaginolysin is an important pore forming toxin, that can lyse human red blood cells and the vaginal 
epithelium resulting in tissue damage (35). In the case of BV, it has been shown that certain species of 
Lactobacillus produce inhibitory compounds or bacteriocins which act against G. vaginalis (29). It has 
also been shown in vitro that G. vaginalis produces bacteriocins that are also active against 
Lactobacillus (36).  
  
2.3 Genetic diversity of Gardnerella vaginalis  
  
Differences in virulence factors among the strains of G. vaginalis has been reported using genome 
sequencing (37). In 2010, a study examined the virulence factors for a strain of G. vaginalis from 
individuals diagnosed as BV positive and negative (6). The results of this study were interesting, as they 
found impaired adherence in epithelial cells in the non-BV isolate and suggested that there may be both 
commensal and pathogenic strains of G. vaginalis. However, as in other studies, they did not mention 
any Gram stain characteristics of the woman without BV. Recently, a comparative analysis of 17 clinical 
isolates of G. vaginalis suggested that the species can be subdivided into 4 clades and that there may be 
multiple species of G. vaginalis. Ahmed et al 2012 found that the degree of diversity among the strains 
was exceptionally high for a single species (37). 
 
  
Studies based on 16S rRNA variable region targeted sequencing have been biased against detecting 
Gardnerella (38, 39) , however, one sequencing study distinguished four G. vaginalis subgroups based 
on a single nucleotide difference in variable region of the 16S rRNA gene (40). Santiago et al (32) 
studied 16S rRNA PCR product using Taq I restriction digest and they found that G. vaginalis has 
atleast three genotypes. 
  
  
7 
 
  
2.4 Epidemiology of Bacterial vaginosis (BV)  
  
The prevalence of BV varies from country to country within the same region and within similar 
population groups. The prevalence has been estimated to be in the range 8% - 75% (42). The prevalence 
of BV has been shown to vary between ethnic groups in North America, South America, Europe, the 
Middle East and Asia. Based on a nationally representative sample of women in the United States, the 
prevalence has been estimated to be 21.2 million (29.2%) among women aged 14-49 years old 
(NHANES 2001-2004). The highest prevalence is seen in Africa and lowest in Asia and Europe (9).   
In a recent study in South Africa, women infected with prevalent Herpes Simplex virus-2 (HSV-2) were 
shown to be at high risk for incident BV infections (41). This study investigated the risk of BV infections 
in HIV negative women, however, in a more recent study the prevalence of HSV-2 and HIV co-infection 
was reported to be 41% in South African women (42). Epidemiological data have indicated that the risk 
of BV is increased in women of African ethnicity (43). The possible risk factors of BV include 
population prevalence, socioeconomic and racial characteristics and other behavioural or physical risk 
factors such as smoking, the presence of sexually transmitted infections and underlying immune 
deficiencies such as those associated with HIV infection (44).   
Recent epidemiological studies have sequenced bacterial communities present in BV using the 
molecular approach. According to the 5 to 8 bacterial communities present in the vaginal microbiome 
the data suggested that women with BV are prone to harbouring a specific cluster of microorganisms, 
while women at higher risk due to other established risk factors may harbour other BV-associated 
clusters as well (9). It was further hypothesized that biofilm-producing communities of G. vaginalis 
may play a role in the initiation and perpetuation of symptoms (9). The incidence of G. vaginalis has 
been shown to be significantly higher among women with preterm labour and late miscarriage (45). 
  
2.5 Bacterial vaginosis during pregnancy  
  
Bacterial vaginosis has been associated with preterm birth and poor perinatal outcomes (13). The vaginal 
microbiome in pregnancy plays an important role in both maternal and neonatal health outcomes (13, 
14). A shift in the bacterial community of the vagina is observed during pregnancy to a composition 
that is dominated by one or two species of Lactobacillus. Lactobacillus is believed to inhibit the growth 
of pathogens through secretion of antibacterial bacteriocins as well as the production of metabolites 
such as lactic acid that help to maintain a low pH of 4.5 (46). Dysbiosis of the vaginal microbiome is 
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associated with complications of pregnancy, an increased risk of preterm birth (47). The maternal 
vaginal microbiome may also be an important source of pioneer bacteria for the neonatal gut 
microbiome (47), which have a profound effect on host system metabolism and immunity.  
  
2.6 Diagnosis of BV  
The diagnosis of BV has been problematic due to its complex polymicrobial nature (48). These include 
laboratory-based methods and clinical bedside testing.   
  
2.6.1 Laboratory based method   
Laboratory testing is based on microscopy of gram stained vaginal smears on a glass slide and air dried 
for gram staining by standard methods. The stained slide is examined under oil immersion and several 
bacterial morphotypes are evaluated by a standardized scoring method. Each slide is then graded as per 
the standardized quantitative morphological classification method developed by Spiegel et al (49) and 
later modified by Nugent et al  (50), which assigns a score between 0 and 10 based on the abundance of 
the following various bacterial morphotypes: large Gram-positive rods (Lactobacillus morphotypes), 
small Gram-variable rods (G. vaginalis morphotypes), small Gram-negative rods (Bacteroides spp. 
morphotypes), curved Gram-variable rods (Mobiluncus spp. morphotypes), and Gram-positive cocci. 
Each morphotype is quantitated from 1 to 4+ regarding the number of morphotypes per oil immersion 
field (0, no morphotypes; 1+, less than 1 morphotype; 2+, 1 to 4 morphotypes; 3+, 5 to 30 morphotypes; 
and 4+, 30 or more morphotypes). Scores between 0 and 3 represent “normal vaginal flora,” scores 
between 4 and 6 represent “intermediate vaginal flora,” and scores between 7 and 10 are considered 
positive for BV. Nugent scoring is considered the standard method for BV diagnosis in research studies 
(50). Although highly accurate, this technique requires specialized training and is subjective, and 
microscopic evaluation is not widely available for clinicians to assist in the diagnosis of BV.   
  
2.6.2 Molecular based methods  
Applications of molecular methods to studies of the vaginal microbiome have not been limited to studies 
of microbially diverse populations and community composition alone but have also been applied as part 
of the diagnostic process for BV (43). Molecular techniques are well known for their high performance 
as they detect specific bacterial nucleic acids. Molecular techniques offer a wide range of advantages 
over microscopic techniques as they can detect fastidious bacteria, enable quantitation and most 
importantly they are highly sensitive when it comes to self-collected vaginal swabs. Several studies 
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have evaluated PCR assays for BV diagnosis (51-53) and obtained excellent results. Direct probe assays 
present a DNA probe to a vaginal fluid sample. The DNA probe binds specific sequences from a 
bacterium and can detect the presence of different bacteria in a single sample.   
  
  
2.6.3 BD Max vaginal panel  
 
The BD MAX vaginal panel is the quantitative real-time multiplex PCR assay (Becton Dickinson, 
Sparks, MD) that recently received FDA market authorization for the diagnosis of vaginitis in 
symptomatic women. The assay provides a positive or negative result for BV, Candida group (C. 
albicans, C. tropicalis, C. parapsilosis, and C. dubliniensis), C. glabrata or C. krusei, and Trichomonas 
vaginalis (54). It incorporates an automated DNA extraction and real time polymerase reaction (PCR) 
for the direct, qualitative detection of DNA from vaginal pathogens. This multiplex assay uses a 
proprietary algorithm to diagnose BV that includes a quantitative assessment of Lactobacilli (L. 
crispatus and L. jensenii), G. vaginalis, A. vaginae, Megasphaera type 1, and BV associated bacteria 
(BVAB2) (54). 
  
2.6.4 Clinical methods  
  
Clinically, the criteria that is mostly used is the Amsel’s criteria, which requires at-least three of the 
following criteria to be met. The presence of clue cells constituting at-least 20% of vaginal epithelial 
cells in the vaginal fluid, an elevated vaginal pH of greater than 4.5, a release of a fishy (amine) odor 
upon addition  of 10% potassium hydroxide to the vaginal fluid (48) and the presence of homogenous, 
non-viscous milky discharge adherent to vaginal walls . The production of amines results in an increased 
pH and favors the growth of other anaerobes that are associated with BV.  Diagnosis based upon clinical 
signs without laboratory testing has 90% sensitivity but only 77% specificity (55).  
  
2.7 Rationale for the proposed study  
Currently there is a lack of published data on the genetic diversity of the 16S ribosomal RNA (rRNA) 
and sialidase A gene from G. vaginalis strains isolated from BV intermediate and positive pregnant 
women. This study is novel since it will be the first to explore the genetic diversity of positive and 
10 
 
intermediate G. vaginalis strains in South African pregnant women. By conducting this study, we would 
be able to shed light on the diversity of the strains of G. vaginalis in this population. Additionally, this 
would also give us an idea on therapeutic interventions as to whether the intermediate group should also 
be considered for treatment since the treatment focuses more on BV positive women.   
  
  
2.8 Study objectives  
  
2.8.1 To perform Nugent scoring on vaginal swabs to select BV intermediate and BV positive 
samples  
2.8.2 To amplify the 16S rRNA gene of G. vaginalis from BV intermediate and BV positive 
samples by conventional PCR  
2.8.3 To analyze the diversity in the 16S between positive and intermediate cases by sequencing 
and phylogenetic analyses  
2.8.4 To detect and quantify the sialidase A gene of G. vaginalis by conventional PCR and 
droplet digital (ddPCR)  
2.8.5 To analyze the diversity of the sialidase A gene between positive and intermediate cases 
by sequencing and phylogenetic analyses  
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CHAPTER THREE  
 METHODS  
3.1 Ethics approval  
The study was approved by the Biomedical Research Ethics Committee (BREC) of the University of 
KwaZulu-Natal (BE274/18).   
  
3.2 Study design and setting  
This study was a sub-study of a larger study which focused on laboratory-based detection of vaginitis 
pathogens in pregnant women. The larger study included n=354 women, 18 years and older who were 
willing to provide written informed consent and willing to be tested for vaginal pathogens. The study 
population was recruited from the King Edward VIII hospital in Durban, South Africa. The women 
were classified as BV positive and intermediate using the Nugent Scoring criteria on gram-stained 
vaginal smears. A 100% in-house quality control check on the gram-stained slides was performed.  The 
study was conducted at the School of Clinical Medicine Research Laboratory at the Nelson R. Mandela 
School of Medicine, University of KwaZulu-Natal.   
  
3.3 Laboratory procedures  
3.3.1 Nugent scoring for grading of vaginal smears  
  
Smears were prepared from vaginal swabs and rolled onto glass slides. The slides were gram stained 
and examined under the oil immersion objective. Each slide was then graded as per the standardized 
quantitative morphological classification method developed by Nugent et al (50), which has been 
described in the literature review.  
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3.3.2 DNA extraction   
DNA was extracted from the vaginal swabs using a commercially available kit, Purelink Microbiome 
DNA purification kit (Thermofischer Scientific, Invitrogen, Carlsbad, USA) according to 
manufacturer’s instructions.   
Briefly, 2 ml of DNA samples were centrifuged for 30 minutes at 14 000 xg. The supernatant was 
discarded and 800 µl of S1 lysis buffer was added to the pellet and pipetted up and down to mix the 
sample. The sample was then transferred to the bead tube and 100 µl of S2 lysis enhancer was added to 
the bead tube, capped and vortexed briefly. This was incubated at 950C for 10 minutes, followed by 
vortexing at a maximum speed for 7 minutes and further centrifuged at 14 000 xg for 1 minute. 
Thereafter, 500 µl of the supernatant was transferred to a clean microcentrifuge tube, avoiding the bead 
pellet and any cell debris. To bind DNA to the column, 900 µl of binding buffer was added and vortexed 
briefly. Following this, 700 µl of the sample mixture was loaded onto a spin column-tube and 
centrifuged at 14 000 xg for 1 minute. The flow through was discarded and the spin column was 
centrifuged at 14 000 xg for 30 seconds. The spin column was placed in a clean tube, 50 µl of S6 elution 
buffer was added, the tube was incubated at room temperature for 1 minute. After 1 minute, the spin 
column was centrifuged at 14 000 xg for 1 minute, and the column was discarded and the purified DNA 
was stored at -200C.  
  
3.3.3 PCR amplification of the 16S ribosomal region of Gardnerella vaginalis  
  
To confirm the presence of G. vaginalis DNA in the extracted sample, a bacterium specific 16S 
ribosomal RNA (rRNA) PCR was performed for G. vaginalis. The PCR primers and cycling conditions 
used were as per (55). The following forward (5’GGGCGGGCTAGAGTGCA-3’) and reverse primer 
pairs (5’GAACCCGTGGAATGGGCC-3’) were used in the amplification reactions. The PCR 
conditions were as follows: an initial denaturation at 95ºC for 10 minutes followed by 40 cycles of 95ºC 
for 30 seconds (denaturation), annealing was performed at 55 C for 30 seconds and extension at 72ºC 
for 30 seconds, followed by a final extension at 72ºC for 7 minutes. All PCR reactions were performed 
using a T100 thermocycler (BioRad). The PCR products were separated on a 1% agarose gel and viewed 
under a UV transilluminator (GENE GENIUS).  
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3.3.4 Detection of the sialidase A gene by PCR  
The presence of the sialidase A gene was detected using the following specific primers; forward  
GVAGSIAF  (GACGACGGCGAATGGCACGA)  and  reverse  GVAGSIAR  
(TACAAGCGGCTTTACTCTTG).  The PCR conditions were as follows: an initial denaturation at 
950C for 10 minutes followed by 40 cycles of denaturation at 950C for 30 seconds, annealing was 
performed at 580C for 1 minute and extension at 720C for 2 minutes, this was followed by final extension 
at 720C for 7 minutes. All PCR reactions were performed using a T100 thermocycler (BioRad). PCR 
products were separated on a 1% agarose gel and viewed under a UV transilluminator (GENE 
GENIUS).   
  
3.3.5 Sequencing of 16S rRNA and sialidase A PCR amplicons   
The PCR amplicons were sequenced using the Sanger method at Inqaba Biotechnological Industries in 
Pretoria, South Africa. The amplicons were sequenced using an ABI3500XL genetic analyser. The raw 
sequencing data was edited using Chromas software V2.6.5 (Technelysium.com).  
  
3.3.6 Quantification of sialidase A gene by droplet digital PCR (ddPCR)  
A total of 2.5ul of extracted DNA was used in the 20ul ddPCR reaction with the 2x digital PCR 
EvaGreen supermix. Primers specific to the sialidase A gene were added to the PCR mix (forward 
primer (GACGACGGCGAATGGCACGA); reverse primer (TACAAGCGGCTTTACTCTTG).  
Droplets were generated using the manual droplet generator (Bio-Rad), droplet generation oil for 
EvaGreen (Bio-Rad) and the PCR mix containing the sample. A total of 40ul of droplets were used for 
the PCR reaction, with the following conditions; 95℃ for 10 min, 40 cycles of 94℃ for 30 sec and  
60℃ for 1 min, and 98℃ for 10 min. Samples were read on the QX200 Droplet Reader (Bio-Rad) using 
the QuantaSoft Software and acquired on Ch1 for FAM. Analysis was performed on the QuantaSoft 
Software using manual thresholding. Statistical analysis was performed on GraphPad Prism 5.   
  
3.4 Phylogenetic analysis  
Phylogenetic trees were constructed using the neighbour-joining (NJ) method based on nucleotide 
distances calculated by Kimura’s 2-parameter method across relevant segments of the alignment. Gaps 
were excluded on a pairwise basis. The NJ tree generated was the result of 1000 bootstrap replications 
from a ClustalW multiple alignment. The PHYLogeny Inference Package (PHYLIP) was used for the 
phylogenetic analysis.   
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3.5 Data analyses  
Statistical analyses, including means values, standard deviations, standard errors, p values and 95% 
confidence intervals (CI) was performed using Graph Pad Prism 5.   
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CHAPTER 4 
RESULTS 
4. Demographic results  
4.1 Characteristics of the study population  
  
Table 1 describes the characteristics of the study population. Within the BV intermediate group, a higher 
proportion of the women were between the age of 2529 years old (41.18%). A higher proportion of 
women in this group did not complain of abnormal vaginal discharge (67.65%). Most women who had 
been diagnosed as BV intermediate were unmarried (91.18%), had completed high school (79.41%), 
had a regular sexual partner (79.41%), had experience first sex at 15-20 years of age (82.35%), had 
between 2-4 life time sex partners (47.06%) and did not practise condom use at their last sex act 
(82.35%) respectively. In addition, most women who were intermediate were in the third trimester of 
pregnancy (58.82%). 
For the women who were diagnosed as BV positive, similarly to the intermediate group, most women 
who were between the ages of 25-29 years (33.33%), did not complain of abnormal discharge (64.81%) 
had completed high school (64.81%) and were unmarried (92.59%). A higher proportion of BV positive 
women were also in the third trimester of pregnancy (51.85%), did not use condoms(62.96%). and has 
2-4 life-time sex partners (48.15%). 
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Table 1: Characteristics of the study population   
 
BV Intermediate BV Positive Total 
 
N  Percentage  N  Percentage N Percentage 
Number sampled 34  38.6 54  61.4 88  100 
Age group 
 
 
 
 
 
 
15-19 1 2.94 2 3.7 3 3.41 
20-24 9 26.47 10 18.52 19 21.59 
25-29 14 41.18 18 33.33 32 36.36 
30-34 6 17.65 13 24.07 19 21.59 
35-39 3 8.82 9 16.67 12 13.64 
40-44 1 2.94 2 3.7 3 3.41 
Current abnormal 
vaginal discharge 
 
 
 
 
 
 
No 23 67.65 35 64.81 58 65.91 
Yes 11 32.35 19 35.19 30 34.09 
Educational level 
 
 
 
 
 
 
College/University 7 20.59 15 27.78 22 25.00 
High school 27 79.41 35 64.81 62 70.45 
Primary school 0 0 4 7.41 4 4.55 
Married 
 
 
 
 
 
 
No 31 91.18 50 92.59 81 92.05 
Yes 3 8.82 4 7.41 7 7.95 
Regular sex partner 
 
 
 
 
 
 
No 7 20.59 4 7.41 11 12.50 
Yes 27 79.41 50 92.59  77 87.50 
Cohabiting       
No 19 55.88 34 62.96 53 60.23 
Yes 15 44.12 20 37.04 35 39.77 
Age of first sex       
15-20 28 82.35 42 77.78 70 79.55 
21-25 5 14.71 7 2.96 12 3.64 
<15 0 0 4 7.41 4 4.55 
>25 1 2.94 1 1.85 2 2.27 
No of lifetime sex 
partners 
      
1 11 32.35 14 25.93 25 28.41 
2-4 16 47.06 26 48.15 42 47.73 
>4 7 20.59 14 25.93 21 23.86 
Partner has other 
partners 
      
Don’t know 14 41.18 19 35.19 33 37.5 
No 11 32.35 14 25.93 25 28.41 
Yes 9 26.47 21 38.89 30 34.09 
Condom used 
during last sex act 
 
 
 
 
 
 
No 28 82.35 34 62.96 62 70.45 
Yes 6 7.65 20 37.04 26 29.55 
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Trimester 
pregnancy 
      
1st 6 17.65 9 16.67 15 17.05 
2nd 8 23.53 17 31.48 25 28.41 
3rd 20 58.82 28 51.85 48 54.55 
 
4.2 LABORATORY RESULTS  
4.2.1 Diagnosis of BV based on Nugent scoring  
To classify pregnant women as either BV positive or BV intermediate, vaginal smears were assessed by 
the Nugent scoring criteria. Of the 354 characterized vaginal swab samples, a total of n=37 intermediate 
cases were identified in the study population. Although n=124 BV positive cases were identified, for 
this study, n=50 positive samples were randomly selected for further analysis.  
  
4.2.2 Amplification of the 16S and sialidase A gene  
The 16S rRNA was successfully amplified using the bacterium specific primers without the need to 
optimize the PCR. All BV positive and BV intermediates samples produced positive amplicons (Fig. 
2). The sialidase A gene was shown to be present in 47/50 (95%) of the BV positive samples and 30/37 
(81%) of the intermediate samples (Fig. 3).  
  
Figure 2: Agarose gel electrophoresis of selected BV positive samples (n=10). Lane 1: 100 bp 
molecular weight marker (Fermentas), Lane 2 – lane 10 (positive bacterial vaginosis samples), 
and Lane 12 Negative control (N.C).  
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Figure 3: Agarose gel electrophoresis of selected BV positive samples (n=10) to confirm the 
presence of the sialidase A gene. Lane 1:100bp molecular weight marker (Fermentas), Lane 2- 
11: BV samples, and Lane 13: Negative control.  
 
 
  
  
Figure 4: Agarose gel electrophoresis of the sialidase A gene of selected BV intermediate samples 
(n=11).  
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4.3 Sequence alignment and Phylogenetic analysis of G. vaginalis 16S rRNA sequences  
To determine the genetic differences in the 16S rRNA across BV positive and intermediates cases, a 
phylogenetic analysis was performed. According to the sequence alignment of all samples analyzed, 
there were no genetic differences in the sequences across the samples (Appendix 1). This was also 
shown in the neighbor joining phylogenetic tree which was constructed (Figure 5). The sequences were 
aligned to study the genetic differences within the 16S rRNA of the G. vaginalis PCR amplicons. The 
sequence alignment was performed using Bioedit.   
Table 2 shows the Basic Local Alignment Search Tool (BLAST) search results for all 16S rRNA 
amplicons that were generated. For both BV positive and intermediates the percent identity to the G. 
vaginalis ribosomal RNA ranged from 90 -100%.   
  
Table 2: Basic Local Alignment Search tool (BLAST) results for 16S rRNA amplicons of G. 
vaginalis.  
  
Sample 
no.  
Result  % Identity  Accession number  
V01  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.28  gi|1530815055|MH898666.1  
V03  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.36  gi|1530815055|MH898666.1  
V09  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V10  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V11  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.39  gi|1530815055|MH898666.1  
V13  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.52  gi|1530815055|MH898666.1  
V17  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V18  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
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V19  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V21  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V24  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
80  gi|1530815055|MH898666.1  
V27  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V30  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.78  gi|1530815055|MH898666.1  
V31  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.39  gi|1530815055|MH898666.1  
V32  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V35  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V41  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V42  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V44  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V45  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.37  gi|1530815055|MH898666.1  
V47  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.36  gi|1530815055|MH898666.1  
V49  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.39  gi|1530815055|MH898666.1  
V50  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.37  gi|1530815055|MH898666.1  
V52  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V53  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
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V55  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V56  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V57  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V58  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V60  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V64  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V66  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.40  gi|1530815055|MH898666.1  
V67  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V68  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.78  gi|1530815055|MH898666.1  
V69  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V70  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V71  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.37  gi|1530815055|MH898666.1  
V72  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.35  gi|1530815055|MH898666.1  
V73  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V74  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V76  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
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V78  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.37  gi|1530815055|MH898666.1  
 
V81  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V82  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.32  gi|1530815055|MH898666.1  
V83  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V84  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V85  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.37  gi|1530815055|MH898666.1  
V88  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V92  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V93  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.17  gi|1530815055|MH898666.1  
V95  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V96  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V98  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.39  gi|1530815055|MH898666.1  
V101  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.36  gi|1530815055|MH898666.1  
V102  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.79  gi|1530815055|MH898666.1  
V103  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V109  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
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V111  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V112  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
 
V116  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V117  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.78  gi|1530815055|MH898666.1  
V121  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.36  gi|1530815055|MH898666.1  
V123  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.36  gi|1530815055|MH898666.1  
V124  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V126  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.39  gi|1530815055|MH898666.1  
V184  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.36  gi|1530815055|MH898666.1  
V202  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V206  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.58  gi|1530815055|MH898666.1  
V207  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.36  gi|1530815055|MH898666.1  
V239  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.39  gi|1530815055|MH898666.1  
V240  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.78  gi|1530815055|MH898666.1  
V250  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.36  gi|1530815055|MH898666.1  
V258  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.78  gi|1530815055|MH898666.1  
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V269  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.39  gi|1530815055|MH898666.1  
V270  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.36  gi|1530815055|MH898666.1  
V276  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.61  gi|1530815055|MH898666.1  
V277  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.78  gi|1530815055|MH898666.1  
V281  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
100  gi|1530815055|MH898666.1  
V292  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99  gi|1530815055|MH898666.1  
V312  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.79  gi|1530815055|MH898666.1  
V319  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.37  gi|1530815055|MH898666.1  
V320  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
95.65  gi|1530815055|MH898666.1  
V324  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.79  gi|1530815055|MH898666.1  
V328  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.73  gi|1530815055|MH898666.1  
V343  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
99.37  gi|1530815055|MH898666.1  
V350  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
98.78  gi|1530815055|MH898666.1  
V353  G. vaginalis strain UGent25.49 16S rRNA, partial 
sequence  
  
99.37  gi|1530815055|MH898666.1  
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Figure 5: The evolutionary history was inferred using the UPGMA method. The optimal tree is 
shown. The percentage of replicate trees in which the associated taxa clustered together in the 
bootstrap test (500 replicates) are shown next to the branches. The tree is drawn to scale, with 
branch lengths in the same units as those of the evolutionary distances used to infer the 
phylogenetic tree. The evolutionary distances were computed using the Maximum Composite 
Likelihood method. Phylogenetic analyses were conducted in MEGA4. 
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4.4 Quantification of Sialidase A gene by Droplet digital PCR  
Droplet digital PCR enables absolute quantification of nucleic acids in a sample. In the present study, 
77 DNA extracts were tested (47 BV positives and 30 BV intermediates).  These were confirmed to 
contain the sialidase A gene by conventional PCR. EvaGreen Supermix for probes and droplet 
generation oil was used, forward and reverse primers were also used. A high number of sialidase A 
copies was observed in BV positive cases compared to BV intermediate cases. However, there are BV 
intermediate cases that had high copy numbers of sialidase A as well. With reference to Table 3, V32, 
V09, V10 BV positives had the highest number of copies of sialidase A 69000, 55600, and 46600 copies 
per 20ul of reactions, respectively. A high copy number of sialidase A was also observed in intermediate 
BV cases, with V116, V72, V124 having a high copy number of 45240, 40940 and 38900 copies per 
20ul respectively.   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 3: Quantification of sialidase A in BV positive  (n=47) and 30 BV intermediate (n=30)  by ddPCR.  
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Copies Poisson Poisson Positive Accepted
per 20uL 
Well
Confidence Confidence Droplets Droplets
Max Min
V01 12,9 258 14,7 11,1 197 17829 18026 10000 Pos
V03 329 6580 339 320 4731 14641 19372 10000 Pos
V09 2780 55600 2830 2730 15883 1652 17535 10000 Pos
V10 2330 46600 2374 2288 15367 2460 17827 10000 Pos
V11 891 17820 909 873 10128 8941 19069 10000 Pos
V13 2,9 58 3,8 2,1 48 19541 19589 10000 Pos
V17 9,8 196 11,3 8,3 159 18990 19149 10000 Pos
V18 28 560 30,5 25,4 461 19152 19613 10000 Pos
V19 444 8880 456 432 5469 11923 17392 10000 Pos
V21 412 8240 424 401 4957 11815 16772 10000 Pos
V24 3,9 78 5 3 56 16833 16889 10000 Pos
V27 1217 24340 1241 1193 11073 6108 17181 10000 Pos
V31 221 4420 229 213 2999 14533 17532 10000 Pos
V32 3450 69000 3530 3370 14608 824 15432 10000 Pos
V35 155 3100 162 149 2196 15562 17758 10000 Pos
V42 1082 21640 1103 1061 10974 7275 18249 10000 Pos
V44 3,7 74 4,7 2,9 64 20248 20312 10000 Pos
V45 4 80 5 3,1 68 20006 20074 10000 Pos
V47 92,4 1848 97 87,8 1552 19000 20552 10000 Pos
V49 2,3 46 3,1 1,6 37 18932 18969 10000 Pos
V50 886 17720 904 869 10000 8897 18897 10000 Pos
V53 326 6520 336 316 4344 13615 17959 10000 Pos
V55 73,6 1472 77,7 69,5 1212 18777 19989 10000 Pos
V57 152 3040 158 146 2374 17248 19622 10000 Pos
V58 26,1 522 28,6 23,6 404 18013 18417 10000 Pos
V60 1865 37300 1900 1832 14336 3693 18029 10000 Pos
V64 28,1 562 31,5 24,8 276 11398 11674 10000 Pos
V67 144 2880 150 138 2171 16633 18804 10000 Pos
V68 18,2 364 20,3 16,2 303 19396 19699 10000 Pos
V69 1047 20940 1067 1027 11008 7672 18680 10000 Pos
V73 5,9 118 7,2 4,8 98 19376 19474 10000 Pos
V74 72,4 1448 76,4 68,3 1221 19242 20463 10000 Pos
V76 94,3 1886 99,1 89,5 1478 17713 19191 10000 Pos
V81 3530 70600 3610 3460 18200 951 19151 10000 Pos
V83 434 8680 445 423 5868 13161 19029 10000 Pos
V84 33,4 668 36,2 30,6 560 19450 20010 10000 Pos
V88 162 3240 170 154 1637 11111 12748 10000 Pos
V92 3890 77800 3980 3800 17190 654 17844 10000 Pos
V98 75,4 1508 79,7 71,1 1171 17700 18871 10000 Pos
V103 4,5 90 5,6 3,6 77 19907 19984 10000 Pos
V109 4,9 98 6 3,9 78 18765 18843 10000 Pos
V111 24,2 484 26,6 21,8 390 18774 19164 10000 Pos
V112 126 2520 133 120 1463 12935 14398 10000 Pos
V116 2262 45240 2304 2221 15219 2607 17826 10000 Pos
V121 15 300 16,6 13,3 316 24690 25006 10000 Pos
V123 14,4 288 16,2 12,6 246 19967 20213 10000 Pos
V124 1945 38900 1980 1911 15496 3668 19164 10000 Pos
V56 10,2 204 11,8 8,7 173 19804 19977 10000 Int
V72 2047 40940 2083 2012 16115 3431 19546 10000 Int
V78 1008 20160 1035 981 5603 4134 9737 10000 Int
V85 1,4 28 2,1 0,9 24 19783 19807 10000 Int
V93 1,8 36 2,5 1,2 28 18584 18612 10000 Int
V95 1,5 30 2,2 1 25 19704 19729 10000 Int
V102 2,3 46 3,1 1,6 37 18953 18990 10000 Int
V117 3 60 3,9 2,2 48 18862 18910 10000 Int
V126 700 14000 716 685 8213 10099 18312 10000 Int
V184 2,1 42 2,9 1,4 32 18287 18319 10000 Int
V202 697 13940 713 681 7682 9500 17182 10000 Int
V206 51 1020 54,6 47,4 773 17436 18209 10000 Int
V207 1095 21900 1117 1074 10504 6832 17336 10000 Int
V250 300 6000 309 290 3879 13371 17250 10000 Int
V269 5,7 114 7 4,6 88 17995 18083 10000 Int
V270 1 20 1,7 0,6 13 14601 14614 10000 Int
V276 0,63 12,6 1,12 0,32 10 18568 18578 10000 Int
V277 14 280 15,8 12,2 228 19048 19276 10000 Int
V281 6,5 130 7,9 5,3 95 17200 17295 10000 Int
V289 12,3 246 14,1 10,6 189 17923 18112 10000 Int
V292 1370 27400 1396 1345 12148 5508 17656 10000 Int
V312 190 3800 199 181 1867 10649 12516 10000 Int
V319 2 40 2,8 1,4 30 17801 17831 10000 Int
V320 0,74 14,8 1,24 0,39 12 19109 19121 10000 Int
V324 349 6980 359 339 4688 13590 18278 10000 Int
V328 845 16900 866 823 6258 5960 12218 10000 Int
V343 3,1 62 4,2 2,1 34 13006 13040 10000 Int
V350 580 11600 594 567 7121 11169 18290 10000 Int
V353 36,1 722 39,2 33,1 546 17511 18057 10000 Int
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ul
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4.5 Sialidase A gene copy number in relation to BV status  
Following ddPCR, sialidase A copy numbers in association with BV positives and BV intermediates 
was investigated (Fig. 6). In the BV positive group the mean value was 13374 (95% CI 7203-19545) 
and in the intermediate group the mean value was 5760 (95% CI 1941-9579).  The mean value of BV 
positives in association with sialidase A was high (double the mean value of the BV intermediates). 
According to Fig.6 the average copies of sialidase A per cell is significantly much higher in the BV 
positive group when compared to the BV intermediate group.  
  
 
 BV positive Intermediate 
  
Figure 6: Sialidase A copy numbers associated with the BV positive and BV intermediate groups, 
p=0.002.  
 
To further analyze these results, the number of copies of sialidase A in each sample was compared with 
the presence or absence of clinical symptoms of BV namely, abnormal vaginal discharge (Figure 7). 
Interestingly, of the 77 samples analyzed, 25 (32 %) of the participants had abnormal vaginal discharge 
and 52 (68 %) had no discharge. The mean value in the group with the presence of discharge was 14 
536 (95% CI 6545- 22527) whereas with the group reporting no discharge the mean value was 8422 
(95% CI 3681-13163); p= 0.003. According to Figure 7, there is a significant difference between the 
two groups. The high copy numbers of sialidase A gene was associated with the presence of discharge.  
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 Present Absent 
Clinical symptoms 
  
Figure 7: Association of sialidase A copy numbers with the presence or absence of BV clinical 
symptoms (abnormal vaginal discharge); p= 0.033.  
  
  
4.6 Sequencing and phylogenetic analysis of sialidase A gene  
A subset of 20 sialidase A amplicons were sequenced, BV positives (n=13) with high copy numbers of 
sialidase A and BV intermediates (n=7) with low copy numbers for sialidase A. However, after 
sequencing, 5 BV intermediate samples were available for the phylogenetic analysis since 2 samples 
did not sequence properly and were excluded from the analysis.  
With reference to Table 4 which shows BLAST search results of sialidase A gene sequences, the percent 
identity ranged from 91- 100% for most samples with only V81 showing 100% identity to G. vaginalis 
sialidase A gene.  
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Table 4: Basic Local Alignment Search tool (BLAST) results for sialidase A gene amplicons of G.  
vaginalis.  
  
Sample  Result  % identity  Accession no.  
V01  Gardnerella vaginalis strain 79.2 
sialidase A gene, complete cds   
94.47  gi|1349730490|MG737374.1  
V03  Gardnerella vaginalis strain 60.1 
sialidase A gene, complete cds   
92.93  gi|1349730488|MG737373.1  
V10  Gardnerella vaginalis strain 114.2 
sialidase A gene, complete cds   
91.01  gi|1349730494|MG737376.1  
  
V11  Gardnerella vaginalis strain 60.1 
sialidase A gene, complete cds   
97.97  gi|1349730488|MG737373.1  
V17  Gardnerella vaginalis strain 114.2 
sialidase A gene, complete cds   
94.76  gi|1349730494|MG737376.1  
V19  Gardnerella vaginalis strain 58.4 
sialidase A gene, complete cds   
94.18  gi|1349730486|MG737372.1  
V35  Gardnerella vaginalis strain 86.1 
sialidase A gene, complete cds   
91.96  gi|1349730492|MG737375.1  
V42  Gardnerella vaginalis strain 60.1 
sialidase A gene, complete cds   
90.43  gi|1349730488|MG737373.1  
V73  Gardnerella vaginalis strain 60.1 
sialidase A gene, complete cds   
76.53  gi|1349730488|MG737373.1  
V81  Gardnerella vaginalis strain 58.4 
sialidase A gene, complete cds   
100  gi|1349730486|MG737372.1  
V116  Gardnerella vaginalis strain 58.4 
sialidase A gene, complete cds   
94.15  gi|1349730486|MG737372.1  
V121  Gardnerella vaginalis strain 60.1 
sialidase A gene, complete cds   
89.50  gi|1349730488|MG737373.1  
V123  Gardnerella vaginalis strain 60.1 
sialidase A gene, complete cds   
91.62  gi|1349730488|MG737373.1  
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V184  Gardnerella vaginalis strain 60.1 
sialidase A gene, complete cds   
92.22  gi|1349730488|MG737373.1  
V202  Gardnerella vaginalis strain 60.1 
sialidase A gene, complete cds   
95.19  gi|1349730488|MG737373.1  
V207  Gardnerella vaginalis strain 60.1 
sialidase A gene, complete cds   
96.48  gi|1349730488|MG737373.1  
V277  Gardnerella vaginalis strain 60.1 
sialidase A gene, complete cds   
95.16  gi|1349730488|MG737373.1  
V281  Gardnerella vaginalis strain 60.1 
sialidase A gene, complete cds   
95.96  gi|1349730488|MG737373.1  
  
The sequences were aligned to study the genetic differences between the sialidase A gene from BV 
positive and intermediate cases. Appendix 2 shows the sequence alignment of 13 BV positive and 5 BV 
intermediate sequences. Comparing the alignment and the phylogenetic tree (Figure 8) the sequences 
that harbour the same mutations clustered together in the phylogenetic tree. Sample V17 (BV positive) 
and V184 (BV intermediate) clustered together in (Figure 8) and share a common mutation at position 
A38G in both sequences and at position A65C (Appendix 2). Samples V116, V123, V207, V277 and V 
281 also harboured the same mutations at position 21 whereby G was replaced by Cytosine (C) and at 
position A38R. According to the phylogenetic tree, BV intermediate samples were distributed across 
the tree (Figure 8).  
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Figure 8: Phylogenetic tree analysis of sialidase A of BV positive (black) and BV intermediate 
(red). ClustaW multiple alignment was used to create a Neighbour-joining tree with 1000 
bootstrap replications. The phylogenetic tree revealed two major clades of sialidase A gene.  
  
Interestingly, the phylogenetic tree analysis (Figure 8) revealed 2 major clades of the sialidase A gene.  
Samples V01, V73, V19, V116, V202, V81, V11, V207 V281 and V10 clustered in the upper clade 
(Clade 1) and samples V73, V19, V184, V17, V277, V121, V35, V123, V42 and V03 clustering in the 
lower clade (Clade 2). The BV intermediates (in red) clustered in Clade 1 with BV positives (in black) 
and they all harbored a high copy number of sialidase A. Similar observations were made for Clade 2. 
Following, the phylogenetic analysis the copies of sialidase A obtained from (ddPCR) were compared 
to the genetic information obtained from sequencing (Appendix 2). Interestingly, clade 2 (V184, V17, 
V121, V35, V123, V42, V03) seemed to have more samples with lower copies while clade 1 contained 
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samples with higher copies of sialidase A. The average copies for clade 2 was 4,053 while the average 
copies for clade 1 was 22,548 (an estimated 6-fold increase). As shown in Figure 9, there is a strong 
correlation between the genetic sequences and the number of copies of the sialidase A gene.   
  
  
 
 Clade 1 Clade 2 
  
Figure 9: Graph showing the copy numbers of sialidase A in relation to the genetic sequences.  
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CHAPTER FIVE  
DISCUSSION  
 
Gardnerella vaginalis is strongly associated with bacterial vaginosis (BV), and is one of the most 
frequently isolated bacteria from women with symptoms of BV (56). Abundance of G. vaginalis in 
vaginal samples has also been associated with infertility and preterm labour (57). The role of G. 
vaginalis in vaginal disease remains incompletely understood due to its presence in both healthy and 
BV-type vaginal microflora. To the best of our knowledge, no studies locally have addressed nor studied 
the genetic diversity of intermediate BV in pregnant women thus far. To better understand the diversity 
of strains of G. vaginalis, this study investigated the genetic diversity of this pathogen from two BV 
states, BV positive and BV intermediate cases.   
Comparative genomic analyses of 17 clinical isolates of G. vaginalis in all three BV states suggested 
that the species can be subdivided into 4 clades or that there may be multiple species of G. vaginalis. 
Ahmed et al (58) found that the degree of diversity among the strains was exceptionally high for a single 
species. Genomic sequencing has shown differences in virulence factors among strains of G. vaginalis 
(37). The current study investigated the diversity of the 16S rRNA of G. vaginalis present in BV 
intermediate and positive women. According to the sequence alignment of all samples analyzed, there 
were no genetic differences in the sequences across the BV intermediate and positive samples. In a study 
conducted by Eren, Zozaya et al (59) which explored the diversity of G. vaginalis 16S rRNA in the 
genitourinary tract of monogamous couples suggested that there may be a unique, closely related group 
of G. vaginalis oligo-types found among normal and some intermediate women. However, due the 
relatively limited number of normal and intermediate women, the study required these results to be 
confirmed by additional studies (59). Furthermore, the above-mentioned study employed the use of 
pyrosequencing to investigate G. vaginalis diversity at a low level of taxonomic discrimination. After 
extensive survey of the literature, we were unable to find other studies which explored the diversity of 
the 16S rRNA from G. vaginalis, thereby limiting our discussion. Therefore, the data presented in this 
study adds to the growing body of knowledge regarding the diversity of G. vaginalis especially in a 
pregnant population.  
  
This study also investigated the diversity of the sialidase A gene, the virulence factor of G. vaginalis. 
Sialidase A was not detected in some samples by conventional PCR, however, ddPCR was able to detect 
sialidase A in all the samples as it allows absolute quantification of nucleic acids or absolute count of 
target DNA copies per sample. Locally, no studies have quantified the sialidase A gene of G. vaginalis. 
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A high copy number of sialidase A was observed for both BV positive and intermediate cases. Few 
studies have reported that the presence of sialidase A gene does not necessarily indicate the expression 
and/ or activity of the sialidase enzyme (60). In the current study a high copy numbers of sialidase A 
was associated with the presence of vaginal discharge. In addition, the copy numbers of sialidase A was 
significantly higher in the BV positive group when compared to the BV intermediate group. A clinical 
manifestation of BV is the presence of abnormal vaginal discharge, the high copy number of Sialidase 
A ,the virulence gene should be expected in the presence of discharge as revealed in this study. A future 
study that will be of interest is to investigate the  messenger ribosomal nucleic acid (mRNA) expression 
levels of Sialidase A across the two BV states.  
Upon sequencing of sialidase A gene of G. vaginalis, the phylogenetic tree analysis revealed two major 
clades. Interestingly, both groups, BV positive and intermediates were found across both clades. Some 
BV intermediate samples clustered in clade 1 with the BV positives and they all harboured a high copy 
number of sialidase A. Similar observations was made with clade 2. However, clade 2 contained samples 
with lower copies while clade 1 contained samples with higher copies of sialidase A. Clade 1 showed a 
strong correlation between the genetic sequences and the number of copies of the sialidase A gene when 
compared to clade 2. In a recent study in the USA where they quantified and subtyped non-cultured 
vaginal samples by qPCR, the presence of multiple clades had a high positive association with BV type 
flora (61). In our study population, although the vaginal samples were characterized by Nugent scoring 
criteria there was no significant association between sialidase A copy numbers or clades with respect to 
Nugent score.   
Two recent studies which associated 4 clades with the Nugent scoring results had revealed that clade 4 
had no association with BV, confirming the observations made by Balashov and colleagues. In addition, 
Janulaitiene and colleagues (62) also found that G. vaginalis strains of clade 1 were mostly likely to 
colonize BV positive women and this confirmed the findings made by Balashov et al (61, 62). Balashov 
and colleagues reported that clade 2 of the clades they studied was associated with intermediate vaginal 
flora (NS 4-6), Interestingly, Janulaitiene and collegues findings contradicted this, as they revealed that 
this clade was significantly more common in samples with high Nugent score (NS 7-10).  These two 
studies used different PCR techniques, singleplex, conventional, clade specific PCR (for samples from 
Lithunian women) and multiplex qPCR for the samples from the USA. While in the current study we 
employed conventional PCR and droplet digital PCR for the quantification of sialidase A.  
In another study of cpn60 characterization based G. vaginalis subgroups, subgroups of G. vaginalis 
were not evenly distributed among vaginal microbiomes diagnosed as BV positive, intermediate or 
normal based on Nugent score (63). Although G. vaginalis sequences were present in their study group, 
and most women harboured multiple subgroups of G. vaginalis, only subgroup B was significantly more 
abundant in BV positive compared to normal samples. Moreover analysis of pH and clue cells in the 
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samples they studied showed a negative correlation of pH and Nugent score and a positive correlation 
of clue cells and Nugent score (63).   
 Three studies recently reported that it is possible that G. vaginalis has several species with distinct roles 
in BV pathogenesis. Phenotypic diversity within G. vaginalis has also been described in terms of 
virulence factors, particularly production of sialidase. It was reported that there is a possible link 
between symptomatic BV and sialidase production and biofilm formation (32). Genetic heterogeneity 
within G. vaginalis has been demonstrated using amplified ribosomal DNA restriction analysis 
(ARDRA) (64). Santiago and colleagues identified three ARDRA genotypes of G. vaginalis, of which 
only two genotypes (genotypes 1 and 3) produced sialidase. A recent study analysed G. vaginalis 
clinical isolates of three subgroups (clades 1, 2, and 4) with respect to their ability to produce the toxin 
vaginolysin, form a biofilm, and secrete active sialidase. It was also reported that despite the presence 
of the sialidase A gene, some G. vaginalis isolates test negative for sialidase activity. The heterogeneity 
of the published studies that have been conducted on the diversity of G. vaginalis warrants more research 
in this field.   
One limitation of the current study was the small number (n=13) of samples used to construct the 
phylogenetic tree of sialidase A.  Even though the highly sensitive ddPCR was used to quantify the 
sialidase A copy numbers, a larger sample might produce different results of sialidase A gene clade 
distributions in association with sialidase copy numbers and/ or association with BV depending on their 
health status, race, age or geographical location. Despite this limitation, this is the first study to provide 
data on the diversity of G. vaginalis from BV positive and intermediate pregnant women. This study 
has provided the foundation for future studies in our research group which are now are being developed 
on genotyping of G. vaginalis from pregnant women.   
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CHAPTER SIX  
 CONCLUSION  
  
The present study is the first attempt to explore the genetic diversity of strains of G. vaginalis in a 
pregnant population. G. vaginalis has been associated with BV, a condition that increases the risk of 
preterm birth thereby increasing the susceptibility to HIV acquisition. A variety of studies have failed 
to reveal the actual cause of BV using different techniques, especially since G. vaginalis has also been 
isolated from healthy asymptomatic women as well. This also raises questions if the genetic differences 
among strains might distinguish pathogenic strains from commensal strains. In the present study the 
16S rRNA sequences of the G. vaginalis from BV intermediate and positive women showed that there 
is no genetic diversity in the 16S rRNA of G. vaginalis detected in BV positive and intermediate 
samples. The phylogenetic tree of sialidase A gene sequences of intermediate and positive BV revealed 
two major clades which showed differences related to sialidase A copy number. Some of the 
intermediate cases showed high copy numbers for the virulence gene and clustered with the BV positive 
cases. The high copy numbers of the sialidase A gene was associated with the presence of abnormal 
discharge. Lastly, the biogenetic sequences of sialidase A were associated with high copies numbers of 
the virulence factor.  This calls for future studies that focus on the treatment of BV in intermediate cases. 
This is especially important for pregnant women since BV has been linked to considerable 
gynaecological and obstetric morbidity such as preterm delivery, pelvic inflammation disease and upper 
genital tract infections.  
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APPENDIX  
  
Appendix 1: Sequence alignment of 16SrRNA G. vaginalis.  
  
                     10       20        30        40        50        60        70        80        90        100       110      120       130                              
             
            ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....   
V01_GVAGF   ACACCAATGGCGAAGGCAGGTCTCTGGGCTGTTACTGACCTGAGAAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGACGCTGGATGTGGGGCCCATTCCACGGGTTCA   
V03_GVAGF   ......................................G...................................................................................................    
V09_GVAGF   .......................................G...................................................................................................    
V10_GVAGF   .......................................G...................................................................................................    
V11_GVAGF   .......................................G...................................................................................................    
V13_GVAGF   ----.C....................................................................................................................................    
V17_GVAGF   .......................................G...................................................................................................    
V18_GVAGF   .......................................G...................................................................................................    
V19_GVAGF   .......................................G...................................................................................................    
V21_GVAGF   .......................................G...................................................................................................    
V24_GVAGF   .GC.TC...CTCC...-....G.GA.TA...G.......CA.C.C.......TTTT.T.AATT---.T.....A.A...........-...................................................    
V27_GVAGF   .......................................G...................................................................................................    
V31_GVAGF   .......................................G...................................................................................................    
V32_GVAGF   .......................................G...................................................................................................    
V35_GVAGF   .......................................G...................................................................................................    
V41_GVAGF   .......................................G...................................................................................................    
V42_GVAGF   .......................................G...................................................................................................    
V44_GVAGF   .......................................G...................................................................................................    
V45_GVAGF   --------------.........................G................................................................................. ..................    
V47_GVAGF   .....................-.................G......................................................................................... ..........    
V50_GVAGF   .....................-CTCT.............G......................................................................................... ..........    
V52_GVAGF   .......................................G...................................................................................................    
V53_GVAGF   .......................................G................................................................... ................................    
V55_GVAGF   .......................................G...................................................................................................    
V57_GVAGF   .......................................G...................................................................................................    
V58_GVAGF   .......................................G...................................................................................................    
V60_GVAGF   .......................................G...................................................................................................    
V64_GVAGF   .......................................G...................................................................................................    
V66_GVAGF   .......................................G...................................................................................................    
V67_GVAGF   .......................................G...................................................................................................    
V68_GVAGF   .....................-.................G...................................................................................................    
V69_GVAGF   .......................................G...................................................................................................    
V73_GVAGF   .......................................G...................................................................................................    
V74_GVAGF   .......................................G...................................................................................................    
V76_GVAGF   .......................................G...................................................................................................    
V81_GVAGF   .......................................G...................................................................................................    
V83_GVAGF   .......................................G...................................................................................................    
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V84_GVAGF   .......................................G...................................................................................................    
V88_GVAGF   .......................................G...................................................................................................    
V92_GVAGF   .......................................G...................................................................................................    
V98_GVAGF   .......................................G...................................................................................................    
V103_GVAGF  .......................................G...................................................................................................    
V109_GVAGF  .......................................G...................................................................................................    
V111_GVAGF  .......................................G...................................................................................................    
V112_GVAGF  .......................................G...................................................................................................    
V116_GVAGF  .......................................G...................................................................................................    
V121_GVAGF  .....................-.................G......................................................................................... ..........    
V123_GVAGF  .....................-.................G...................................................................................................    
V124_GVAGF  .......................................G................................................................... ................................  
V126_GVAGF  .......................................G...................................................................................................    
  
 
 
Appendix 2: Sequence alignment of sialidase A gene  
              10        20        30        40        50        60        70        80        90       100                    
       
     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|   
V01  TTTACGTAGACGGATACAGCGAGTCRCACAAYATAGGACAATTMTGGTTTGCAAAYATACCAGAATTARACGCM-GTRAGYATWGGCGAAGACTTGCGCG   
V03  ....................C......................................M.R.R..........-...............A..Y..Y...    
V10  .............T.............................................A.G.G..........-.........................    
V11  ....................C............................................A........-....................A....    
V17  ....................C................G..........................C.........-.........................    
V19  ....................S................R....................................C.........................    
V35  ....................C......................................M.R............-...............R..Y......    
V42  ....................S.....Y..........R.....................M.R.R..........-...............R..Y......    
V73  ....................C.S...M................S..............................-.........................    
V81  ....................C.....................................................-.........................    
V116 ....................C................R.....Y....................M.........-.........................    
V121 ....................C................R.....Y...............M.R.RM..R......-..................Y......    
V123 ....................C................R...K.................M.R.R..........-...........M...R..Y......    
V184 .....K..K..K........C..Y.............G..........................C.........K........................    
V202 ....................C.....................................................R.................Y......    
V207 ....................C................R....................................-.........................    
V277 ....................C................R..........................M..................................   
46 
 
V281 ....................S................G.............................................................    
   
              110       120       130       140       150       160       170       180       190       200            
       
      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|   
V01   GAGTGCGAYTAATGGGCGAAGCTAGAACAGGCGGAATCTACTTTAGCGCACTAACCGAAGGMCAAATCCAAAGAATATCAAGAGTAAAG-CCGCTTGTAA   
V03   ............................R.................Y..R....S..................................-..........    
V10   ......................C.....G..A.....T...........G..C....................................-.......W..    
V11   .........................................................................................-..........    
V17   ......................G..........................G....G..................................-..........    
V19   ................M.....Y..........................G.......................................-..........    
V35   .......R........M.....Y.....R.................Y..R....S..................................-..........    
V42   ................M.....Y.....R..Y..............Y..R....S..................................-..........    
V73   ................M.....Y..................................................................-..........    
V81   .........................................................................................-..........    
V116  ................M.....C..........................G....S..................................-..........    
V121  ......................K.....R.................TR.G..W.G..................................G..........    
V123  ......................Y.....R.................Y..R....S..................................-..........    
V184  ........................K....................S...G..T.G..................................-..........    
V202  ......................Y..................................................................-..........    
V207  .........................................................................................-.....K.W..    
V277  ......................Y.....R....................R...........R...........................-..........   
V281  ................A.....C..........................G......................... ..............-.........   
  
  
  
  
 
 
 
 
